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Abstract: Topical treatment modalities have multiple advantages starting with the convenient 
application and non-invasive treatment and ending with the reduction of the risk of the systemic 
side effects. Active pharmaceutical substances must reach the desired concentration at the target site 
in order to produce a particular therapeutic effect. In contrast to other dosage forms topical agents 
applied to the skin may also be susceptible to photodegradation after application. That is why the 
knowledge of the susceptibility of these topical drugs to UV irradiation, which may contribute to their 
degradation or changes in chemical structure, is very important. Active pharmaceutical substances 
used in dermatology may differ both in chemical structure and photostability. Furthermore, various 
factors— such as light intensity and wavelength, pH, temperature, concentration— can influence 
the photodegradation process, which is reflected in particular in kinetics of photodegradation of 
active pharmaceutical substances as well as both the quantitative and qualitative composition of 
by-products. The aim of this study was to conduct a systematic review of the photostability of 
dermatological drugs, as well as of other substances commonly applied topically. The photostability 
of glucocorticosteroids, retinoids, and antifungal drugs as well as non-steroidal anti-inflammatory 
drugs applied topically and selected UV-filters have been discussed. Furthermore, the impact of 
photoinstability on the effectiveness of pharmacotherapy and some photostabilization strategies have 
been also included.
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1. Introduction
Skin is an important administration route of drugs for both topical and systemic therapy. Of all 
available routes of drug administration, the topical application has some advantages. Administration 
of the drug to the skin for systemic effect (1) bypasses the effect of the first pass through the liver, (2) is 
an easy and patient-friendly route of administration, (3) allows some control of the delivery of the 
drug. In recent years, many studies have focused on the application of the drug to the intact and 
healthy skin as an alternative to other routes of administration to achieve systemic effects. Transdermal 
or dermal systems account for approximately 40% of total drug delivery product candidates at the 
stage of clinical trials [1,2]. On the other hand, to achieve local effect, the epicutaneous or topical 
routes of administration are preferred options [3]. As regards local effect, topical administration 
facilitates the safe use of the drug, and reduces the chances of adverse reactions [2,3]. Topical agents 
applied locally to the skin are used in the treatment of skin diseases (e.g., antifungal drugs, antiseptic 
drugs, ultraviolet (UV) radiation-blocking agents, anti-inflammatory, or anti-allergic drugs) or could 
penetrate deeper into local tissues, e.g., drugs used for relieving pain and reducing inflammation of 
muscles and joints. On the other hand, it should be stressed that following topical administration
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the active pharmaceutical ingredient (API) must reach the desired concentration at the target site so 
that it provides a particular therapeutic effect. Appropriate API concentration will be obtained after 
the application of the recommended amount of drug product (a finished dosage form) to the skin [4]. 
The skin is the largest organ of the human body (1.5-2.0 m2) that protects against external environmental 
factors, and thus is exposed to, among others, UV radiation and xenobiotics. Overcoming the barrier 
that constitutes the skin is possible for lipophilic substances with log P in the range of 1-3 and those 
with a low molecular weight (MW < 500 Da) [2]. Therefore, many substances applied topically that 
penetrate through the stratum corneum, reach the dermis and via dermal microcirculation could get 
into the systemic circulation causing systemic effects [2,3,5].
The stability studies of APIs and drug products are a priority in the research and development 
of drugs. Information about the stability of the drug is necessary to ensure its appropriate quality, 
effectiveness, and safety for the patients [6,7]. General rules for conducting stability tests are included in 
the Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products which was 
developed by International Conference on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use [8]. The ultimate goal of the stability studies is to provide industry 
guidance for ensuring the stability of API during all stages of production, packaging and storage. 
The test results provide a basis for determining the durability of a drug product to ensure that 
the medicine is stored properly under the critical environmental conditions (light, humidity, and 
temperature) and will remain in full effect until the end of its useful life. It is commonly known that 
UV irradiation could contribute to the degradation of drug substances and drug products, which could 
have potential consequences in the decrease or loss of their pharmacological activity and thereby have 
an effect on the effectiveness and safety. The crucial issue related to the stress testing studies is the 
photostability testing of new drug substances and products which is included in ICH Q1B [9]. All APIs 
are protected from radiation during storage but during application to the skin, in case of exposure to 
the sun, photodegradation can occur. In addition a very thin layer (about 1 mm) of the drug products 
are often applied directly to the skin. Therefore, it is necessary to specify the photostability of API 
alone, as well as in the presence of other substances, including excipients or cosmetic ingredients [10].
Ultraviolet radiation (UVR) is divided into the following bands: UVA (315-400 nm), UVB (280-315 
nm), and UVC (100-280 nm). All UVC and 95% of UVB radiation are absorbed by the protective 
ozone layer in the stratosphere. UVA and only about 5% of UVB radiation reach the Earth's surface. 
UVC radiation with the highest energy is strongly mutagenic, but only reaches the epidermis; and 
90% of UVB radiation is retained by the stratum corneum and is responsible for the skin erythema 
and immunosuppression. Nucleic acids are the main chromophores for UVB radiation (maximum 
absorption for both DNA and RNA is about 260 nm), that is why there are many mutations, mainly 
UVB fingerprint mutations. However, recent studies have implicated an increase in the role of UVA 
as a carcinogen [11- 13] . UVA radiation is the most important from the point of view of everyday 
life, because it is responsible for the majority of phototoxic and photoallergic reactions, telangiectasia, 
mutagenic, and carcinogenic effects. Research carried out by Huang et al. showed that UVA radiation 
induces mutations in the epidermal basal membrane, where keratinocytes are dividing, which gives 
rise to the skin tumors [14]. It reaches the Earth's surface with relatively equal intensity throughout 
the year, penetrates through the glass, and additionally penetrates deeper into the skin compared 
to UVB radiation, which intensifies its harmful effects. Repeated exposure causes mutations in the 
p53 gene [15] . Depending on the intensity and wavelength, UV irradiation could also affect the 
stability of the drug. According to the guidelines contained in Q1B ICH, the following radiation 
sources are recommended for the photostability tests: (i) xenon or metal-halogen lamp that creates 
artificial daylight, combining the range of visible light and UV with emission standard D65/ID65 
(according to ISO 10977); (ii) simultaneous use of a fluorescent lamp with cold white light with a 
power similar to external daylight according to ISO 10977 and a fluorescent lamp close to UV with a 
range of 320 nm to 400 nm and a maximum emission energy between 250 nm and 270 nm. However, 
interior lighting sources have changed with the adoption of light emitting diodes (LEDs) which may
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increase the risk of photodegradation during the out-of-package in-use period [9,16] . On the other 
hand, several papers discuss ed the lack o f photostability tes ting of pharmac eutical drug sub stances 
during; or after administration. It is therefare necessary to examine how the existing; instruments 
andexisting guidelines aid the understanding of the photostabiliey of topical druge, whieh could be 
exposed to a  significant amount of light after application to the skin [10,17- 21].
Two main categories oi drug products applied topically to the skin are identified: prodects applied 
ior loeel action (creams, gelt, sprays, solution;;) an t products applied for systemic effecCs—transdermal 
drug; delivery rastems. The aim of this study was to condu ct a sys temetic review oS the photost ability 
oi dermatological drugs applied topic ally to the skin for local effect. "The p hotostability ot the most 
important groups of topical drugs used in dermatologty— euch as glucocorticosteroids, retinoids, and 
antifungal deugs— are discussed. In addition, the photostobility of nonsteroidal anti-inflammatory 
drugs (NSAIDs) applied topically as well as selecCed UV-filters is also presented. T ht US Food and 
Drug Administration FDA considers sunscreen products to tie OTC drugs . In Europe, however, the}, 
are considered cosr^etids. The European Union, Australia, and Japan aUow several UV filters that 
are not available in the United States. The FDA lisi eontains only 16 permitted radiation protective 
substances, 11 of them are approved in Europe, however, t ie y  differ in the; values of the maximum 
concentratioos. In Europe, Annex VI to the EU Cosmetics Regulation contams 29 substances, 2 of 
which are physical filters [e2,2l ] . The stability of selected chemical UV filters and (otential interactions 
oo physical UV filters with othet compounds under UV irradiation are discussed. The preliminary 
overview of the current; literature in PubMed bacad on search: photostaaility and drugs identified 
P303 results, including 993 in the last 10 years; photoeegradation and drugs identified 3392 results, 
including 1596 tin tde tast 10 years. Tire results by year are presanted in Figure 1. The percentage of 
main classes of drugs in ahe total amount of the photodegradation seorch are presented in Fidure O. 
The literature search was narrowed down to the particular groups of drugs h sted above. The most 
important groups of drugs Uescribep in the rrticle and examples ot AdIs most relevant drone the point 
of view of phatostability are preseofed in the TaMe t. fiurthermote, the impact t ,  photo instability on 
t ie  safety and effectiveness of pharmacotherapy has been also include!. To the best of onr knowledgo, 
for the first time, an attempt was made to iystematize the data related to the photostabihty of drugs 
applied tep id lty  to the skin.
2018
180
i i photostability and drugs photodegradation and drugs
Figure 1. Results by year based on the search: "photostability and drugs" and "photodegradation and 
drugs" (2008-2018, PubMed).
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Figure 2. Results based on the search for the photodegradation of the main classes of drugs reported 
in PubMed.
Table 1. Selected classes of dermatological drugs described in terms of the photostability.
Drug Class Active Pharmaceutical Ingredient Re if.
Glucocorticosteroids
pregna-1,4-dien-3,20-diones 





















































2. Classes of Drugs
2.1. Topical Glucocorticosteroids
Topical glucocorticosteroids are among the most effective and most commonly used drugs for 
skin diseases. In 1952, Sulzberger and Witten applied for the first time hydrocortisone topically 
for the treatment of skin diseases. Pharmacological action of topical glucocorticosteroids takes 
place through a specific receptor. Glucocorticosteroids bind to cytoplasmic receptors that transport 
the drug to the cell nucleus, where the complex modifies gene transcription. In the nucleus itself 
there are also receptors for the glucocorticosteroids. Then, there is the attachment of regulatory 
DNA sequences, called glucocorticosteroid acting elements (GRE, glucocorticoid response elements),
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which are contained in the regulatory part of the genes coding proteins synthesized in the cell 
response to glucocorticosteroids. These receptors are found both in the epidermis and dermis. 
Topical glucocorticosteroids have anti-inflammatory, anti-proliferative, and immunosuppressive effects. 
The topical side effect is primarily the thinning of the epidermis and dermis [80,81]. Drugs from this 
group are classified according to the strength of topical action in seven groups. W hile creating this 
classification, the physicochemical properties of these drugs, the concentration of the API and its 
affinity for specific receptors were also taken into account. Betamethasone dipropionate belongs to the 
group of the strongest topical glucocorticosteroids, whereas betamethasone valerate is classified as a 
glucocorticosteroid with high potency [82].
The studies on the photostability of glucocorticosteroids laid the foundations for the development 
of modern organic photochemistry [83]. Cross-conjugated glucocorticosteroids—such as prednisolone, 
betamethasone, and triamcinolone—are highly unstable. It has been shown that general patterns in the 
decomposition of corticosteroids under UV irradiation involve rearrangement of cyclohexadienone 
moiety, resulting in two main photoproducts: 'lumiderivatives' and 'photolumiderivatives', and 
as a consequence of side chain loss causing the formation of 'androderivatives' [24,25]. In case of 
betamethasone esters, the photoinstability resulted in generation of photodegradation products, which 
proved to be toxic/phototoxic [26]. The photostability of the hydrophobic betamethasone ester, which 
is easily transported through the skin—betamethasone-17 valerate (9-floro-11p,21-dihydroxy-16p- 
methyl-3,20-dioxopregna-1,4-dien-17-yl pentanoate) has been thoroughly investigated. This synthetic 
glucocorticosteroid is highly photolabile. The photodegradation rate was dependent on solvent dielectric 
constant, ionic strength, buffer concentration, and ingredients used in cream and gel formulations [27]. 
The lower photostability of betamethasone-17 valerate was observed in the gel formulation compared 
to that for the cream formulation. The difference in the composition of the formulations (cream: 
betamethasone-17 valerate 0.1, carbomer (940) 1.5, propylene glycol 8.0, cetostearyl alcohol 7.0, isopropyl 
alcohol 2.0, ethyl paraben 0.2, deionized water 81.0 and gel: betamethasone-17 valerate 0.1, carbomer 
(940) 0.7, hydroxyethyl cellulose 0.5, propylene glycol 20.0, diisopropanolamine 0.5, isopropyl alcohol 
2.0, ethyl paraben 0.2, deionized water 75.9% (w/w) has an impact on the photostability of API. Further 
research on the photostabilization of betamethasone-17 valerate in cream and gel formulations, through 
the use of titanium dioxide, vanillin, or butyl hydroxytoluene showed promising results [27].
The comparative photolysis of betamethasone and its esters: betamethasone-17 valerate and 
betamethasone 21-phosphate (disodium salt) under UVB irradiation has been studied in solution 
and in pharmaceutical dosage forms [25]. Betamethasone 21-phosphate is a water-soluble form of 
parent corticosteroid. Betamethasone-17-valerate was more stable under experimental conditions. 
UVB photolysis of betamethasone-17-valerate in commercial cream was less efficient than in methanol 
solution on exposure to low doses of UVB irradiation (5 J/cm2). Furthermore, betamethasone was more 
stable in methanol than in water, but in both cases the same photoproducts were formed. Chlorocresol 
used as a preservative in this formulation showed photoprotective effect as it possesses the phenolic 
chromophore, which absorbed light in the UVB range [25]. Furthermore, optical properties of the 
dosage form (gel, cream) compared with a solution could also impact on the photostability of APIs. 
Photodegradation of betamethasone is linked with the decrease of its anti-inflammatory activity what 
has been shown in the test on THP-1 cells [25].
Teng et al. characterized degradation pathways for mometasone furoate. This synthetic 
glucocorticosteroid revealed the highest stability at pH < 4; increasing pH and decreasing ionic 
strength decrease the stability of mometasone furoate in aqueous media [28].
The influence of UVB irradiation on the photostability of hydrocortisone 21-acetate in methanol, 
PBS, solid-state and in a commercial cream was investigated by Caffieri et al. [29]. The photolysis 
of hydrocortisone 21-acetate in the commercial cream caused 20% decrease of its concentration. 
The preparation of similar cream with hydrocortisone 21-acetate, but without two parabens (methyl- 
and propyl p-hydroxybenzoates) resulted in faster photolysis of investigated compound. This suggests 
a significant photoprotection effect of the preservatives because of the presence of the phenolic
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chromophore being able to absorb UVB light. A further insight was that the excipients affect not only 
the rate of photolysis, but also the nature of photoproducts formed under irradiation [29].
The solubility of the drug substance in a formulation is also essential for its photostability. 
APIs could be both dispersed or dissolved in a semisolid dosage form. The differences in the 
photostability of API in different bases could be the result of different solubilities in these formulations. 
A possible relationship between solubility and photostability was demonstrated for corticosteroids, e.g., 
hydrocortisone and triamcinolone acetonide [84]. The addition of pigments, e.g., TiÜ2  or ZnO could 
stabilize the APIs by reflecting, scattering, and/or absorbing most of the UV-rays [85]. Because of these 
features, these pigments are used as UV filters in sun creams. TiO2 and ZnO have been proven to be 
useful in photostabilization of photosensitive corticosteroids. The addition of TiO2 or ZnO improved 
photostability of triamcinolone acetonide in basis cream [84].
The experiment carried out by Cacciari et al. showed that the presence of oxygen could have 
special significance to the rate of the photodegradation of corticosteroids. The photodegradation 
process of prednisolone under UVB irradiation was based on the two pathways: direct photolysis and 
self-sensitization via photogenerated reactive oxygen species [30]. The photogeneration of OH*, and then, 
their attack on the corticosteroid could be responsible for the photodegradation process of prednisolone, 
dexamethasone, triamcinolone 16,17-acetonide or fluocinolone 16,17-acetonide [30,31,86,87].
Glucocorticosteroids are also used in the treatment of the scalp diseases. The photostability of 
pharmaceutical preparations during the usage on the scalp is particularly important. Desonide is a 
glucocorticosteroid used topically to relieve inflammatory symptoms and pruritus in diseases such as: 
contact dermatitis, atopic skin inflammation, psoriasis, or lichen planus. The drug was at the forefront 
of the most commonly prescribed steroids in atopic skin lesions. Santa et al. have reported that this 
compound is unstable in the commercially-available hair preparation. After 2 h of UVA irradiation, 
the content of the API decreased below 90%, which at the frequency of application twice a day raises 
concerns as to the maintenance of the therapeutic concentration [33] . In the context of photoinstability, 
particularly important is the investigation of Rosa et al. about the stabilizing effect of benzophenone-3 
on desonide. The results of studies on the photostability of desonide conducted by Rosa et al. indicate 
the protective role played by the addition of benzophenone-3 to the formulation. After 15 h of UVA 
irradiation, there was only 1.49% loss of the active substance, which in comparison to 61% of the loss 
in the case of a commercial product indicates the contribution of the UV filter to the stabilization of 
desonide [34].
Photodegradation of active substances from the steroid group could be a source of new compounds 
of unknown structure and activity. Numerous studies have confirmed the phototoxic potential of 
the topically applied substances and photoproducts formed under UV irradiation. The phototoxic 
potential of triamcinolone 16,17-acetonide has been investigated in in vitro studies. The drug has 
undergone extensive photolysis to three primary photoproducts, which were isolated and then subjected 
to toxicity tests: photohemolysis, linoleic acid peroxidation, protein photodamage, 3T3 photocytotoxicity, 
and DNA photodamage. The phototoxicity or toxicity were proven for two photodegradation 
products of triamcinolone 16,17-acetonide, which was connected with the photosensitizing activity 
of investigated compound. One of the photoproducts, 9a-fluoro-17b-hydroperoxy-11b-hydroxy-16a,17a- 
(1-methylethylidenedioxy)-androsta-1,4-dien-3-one has been proven to be more toxic and phototoxic than 
triamcinolone 16,17-acetonide [87]. The phototoxicity of both the fluocinolone 16,17-acetonide and its 
photoproducts under UVA and UVB irradiation was evaluated. In this case, the most probable mechanism 
of phototoxicity is connected with radicals forming during photodegradation of parent drug under UVB 
irradiation, as well as with reactive oxygen species activity primarily under UVA irradiation [31].
Photostability of flumethazone and flucinolone acetonide was assessed by photoactivation in 
the skin exposed to irradiation so as to determine whether the photodegradation of corticosteroids is 
directly linked with their ability to cause allergic reactions. For this purpose, Miolo et al. used the 
pig skin as ex vivo model as well as bovine serum albumin, proteins, peptides, and amino acids to 
be a source of information on processes occurring in the skin. The photoproducts found in in vitro
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studies were the same as in the case of pig skin after UVB irradiation except flucinolone acetonide 
hydroperoxide which indicates the similarity of the processes occurring in the skin upon UVB exposure 
and the likelihood of photoreactivity of photoproducts in the skin of sun exposed patients [32].
2.2. Retinoids
The problem of acne vulgaris, due to its frequent occurrence and difficulties in treatment, is still 
current. The goal of acne treatment is to reduce the production of sebum, to get rid of micro-nodes 
and to prevent the formation of new ones, to inhibit the development of P. acnes and to reduce 
inflammation [88,89]. Nowadays, three generations of retinoids are distinguished. The first generation 
includes natural compounds: retinol, tretinoin, and isotretinoin. The second generation includes 
monoaromatic synthetic compounds: acitretin and etretinate. The third generation are synthetic 
polyaromatic derivatives, which include adapalene, tazarotene, and bexarotene. Difficulties in assigning 
adapalene to a generation are caused by its different structure (a derivative of 1-naphthalenecarboxylic 
acid). However, based on its similar mechanism of action, adapalene is also included in the third 
generation retinoids [90]. In the treatment of acne vulgaris, topical retinoids (isotretinoin, adapalene, 
tazarotene) are used as monotherapy and in complex products, e.g., adapalene in combination with 
benzoyl peroxide. Tazarotene has been approved for the treatment of acne vulgaris only in the 
US, while in Europe it is used off label. The only retinoid used orally to treat severe forms of acne 
vulgaris and rosacea is isotretinoin. Retinoids are a group of substances of vitamin A activity. In 1982, 
isotretinoin (a tretinoin stereoisomer) was approved for use, which was a breakthrough in the treatment 
of acne. Retinoids act by activating receptors located in the cell nucleus, which leads to the expression 
of appropriate genes. Two families of receptors are distinguished: RAR-receptors for retinoic acid 
and RXR-retinoid receptors X, each of which additionally has three subtypes (a , p, and y). First and 
second generation retinoids can bind to several types of receptors, while third generation retinoids 
are characterized by higher receptor specificity. Topical retinoids for the treatment of acne (tretinoin, 
isotretinoin, and adapalene) affect the process of keratinization, accelerate exfoliation of dead cells, 
and reduce inflammatory changes. Tazarotene is used topically in the treatment of psoriasis, and 
bexarotene in the treatment of cutaneous T-cell lymphoma [90,91].
The following treatment of acne vulgaris is now used: (i) monotherapy with topical retinoid 
or benzoyl peroxide; or (ii) combination therapy with topical retinoid and benzoyl peroxide or 
antibiotic and benzoyl peroxide. Antibiotics used simultaneously (clindamycin, erythromycin) act 
by reducing P. acnes colonization in the skin, inhibiting inflammation, and relieving acne. Benzoyl 
peroxide, on the other hand, is used as a monotherapy or in combined therapy and has non-specific 
antimicrobial activity and limits the development of antibiotic-resistant P. acnes. It is also recommended 
when using a combination medication containing a retinoid (e.g., tretinoin) and an antibiotic (e.g., 
clindamycin). Several compound drugs are available for sale: benzoyl peroxide/adapalene, benzoyl 
peroxide/clindamycin, erythromycin/isotretinoin, and erythromycin/tretinoin.
As a result of using retinoids, the thickness of the stratum corneum is reduced, which in turn 
leads to increased penetration of sunlight into the skin and faster sunburn. Due to the possibility of 
photosensitivity after the application of topical retinoids, it is recommended to avoid the sun and 
use sunscreen creams during increased sun exposure. These medicines should be used with caution 
in patients with previous photosensitivity symptoms. In the case of retinoids used externally in the 
form of creams, gels, and solutions, the therapy is usually started with preparations containing lower 
concentrations of active substances and then it is gradually changed by using preparations with higher 
concentrations. Drugs are administered once a day, usually in the evening, mainly due to the low 
photostability of the first-generation retinoids. Third-generation retinoids, due to modifications of 
their chemical structure, show greater lipophilicity and photostability, and they irritate the skin to a 
lesser extent compared to the first-generation retinoids.
Retinoids are a heterogeneous group of compounds in terms of photostability. Photochemistry 
of retinoids could proceed via, e.g., photoisomerization reactions, photooxygenation reactions,
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and photodegradation. The direction of transformation depends on many factors, including the 
concentration of the substance, drug formulation, exposure time, and type of radiation [92,93]. 
The photostability testing of retinoids reported in the literature is presented in Table 2.
Table 2. Photostability of retinoids reported in the literature.
Retinoid Presen tation  of Sam ples Light Source Irrad iation Tim e/D ose Ref.
A dap alene
-  ethanol solu tion
-  25 m L volu m etric flasks
C A M A G  U V -lam p, S/N 29000, 
dual w av elen g th  254/366 nm  
(Sw itzerland)
day light, 
U V -ligh t 254 nm  
U V -ligh t 366 nm  
irrad iation  tim e— 12 h 
distance— 15 cm
[4 6 ]
A d ap alen e w ith  
ben zoyl peroxide
- ad ap alen e  0.1%  gel and 
10%  benzoyl 
p eroxid e lotion
- 10 m L p lastic syringes
m on och rom atic  sod ium  lam p 
ty p e N A  55 W  (O sram ), and 
fluorescen t ligh tin g  tubes for 
norm al room  lighting
inactin ic light 
actin ic ligh t 
24 h
v isib le  lig h t for 240 h  (1.2 m illion
[4 2 ]
A d ap alene - gel
p h otostability  ch am ber (SU N  
TE ST  X L S+ , A tlas, U SA ).
lu x  h),
U V  ligh t for 250 h 
(200 W  h/m2) 




- 2 g ap p lied  on  40  cm 2 area 
on  th e  v en tral asp ect of 
the forearm s
U V B — L igh t Sources FS72 
T12-U V B-H O  bulbs 
U VA — FS72 T12-B L  HO/50R 
bu lb s covered  w ith  filters 
b lo ck in g  U V B  and low er 
w avelengths.
ph ototh erap y 
U V B  100 to 150 mJ/cm2 
U VA  15 to 22 J/cm2
[4 8 ]
Tretinoin w ith  
ben zoyl peroxide
- tretin oin  0.025%  gel and 
10%  benzoyl 
p eroxid e lotion
- 10 m L p lastic syringes
m on och rom atic  sod ium  lam p 
ty p e N A  55 W  (O sram ), and 
fluorescen t ligh tin g  tubes for 
norm al room  lighting
inactin ic light 




- lotion 0.05%  (w/v) tretinoin
- quartz  cuvette
X B O  450 W  h igh  pressure xenon 
lam p
distan ce of 28 cm  
tem p erature in  the cuvette  never 
exceed ed  36 °C
[4 0 ]
Tretinoin
- RA -lip oso m es
- ethanol solu tion
- 1 cm  quartz  cuvette
ligh t testin g  cab in et Suntest 
C PS+  (H eraeus, M ilan , Italy), 
equ ip p ed  w ith  a X en o n  lam p
ligh t d ose o f 21 k J m in -1  m -2 , 
tem perature o f 25 ° C. 
0 .5 -2 4 0  m in
[3 7 ]
Tretinoin
- tretin oin  (0 .025% ) cream  
spread un iform ly  over the 
cover of a 35 m m  tissue 
cu lture dish
- ethanol so lu tion  (0 .025% ) 
in  E p p end orf 
cen trifuge tubes
so lar sim ulator, m odel 91293, 
(O riel C orp oration , Stratford , 
CT, U SA ) equipped w ith  1000 W  
X en on  lam p 
Luzchem  expo Panels com posed 
of 5 Sylvan ia  8  W  cool w h ite  
ligh t tubes
distance 20 cm  at 365 nm  from  the 
source, the SSL d o se  w as 7.63 
mJ/cm2/sec U VA  and 0.40 
mJ/cm2/sec U V B  rad iation , 
UVB/UVC block in g  filter th e  dose 
at 365 nm  from  the source w as 
5.39 mJ/cm2/sec U VA  rad iation  
w ith  residual 
U V B  dose o f 3.16 pJ/cm2/sec.
[3 6 ]
Isotretinoin
- 13R A -liposom es 
ethanol solu tion
- 1 cm  quartz  cuvette
ligh t testin g  cab in et Suntest 
C P S +  (H eraeus), equ ip p ed  w ith  
a X en on  lam p 
Luzchem  expo Panels com posed 
of 5 Sylvan ia  8 -W  cool w h ite  
ligh t tubes
ligh t dose o f 21 k J m in -1  m -2 , 
tem perature o f 25 ° C. 
0 .5 -2 4 0  m in
[3 7 ]
Isotretinoin
- isotretin oin  (0 .025% ) 
cream  spread  uniform ly  
over th e  cover o f a 35 m m  
tissue  cu lture dish
- ethanol so lu tion  (0 .025% ) 
in  E p p end orf 
cen trifuge tubes
so lar sim ulator, m odel 91293, 
(O riel C orp oration) equ ip p ed  
w ith  1000 W  X en o n  lam p
distance 20 cm  at 365 nm  from  the 
source, the SSL dose w as 
7.63 mJ/cm2/sec U VA  and 
0.40 mJ/cm2/sec U V B  rad iation ; 
d istance 20 cm  at 365 nm  from  the 
source, the dose w as 
5.39 mJ/cm2/sec U VA  rad iation  
w ith  resid ual U V B  dose of 
3.16 pJ/cm2/sec (U V B and  U V C  
blo ck in g  filter)
[3 6 ]
V itam in  A
- form u latio n  sp read  onto 
an  area of 10 cm 2 
(app roxim ately  4  mg/cm2) 
of a glass p late
96000 O riel 150  W  X en on  arc 
so lar sim ulator (O riel 
C orp oration)
UVA/UVB irrad iation  
(2 8 0 -4 0 0  nm ) U V B  dose of 
ap p roxim ately  334.8  mJ/cm2 
30 m in
[3 5 ]
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Vitamin A  refers to several substances with analogous structure that retain the activity of 
retinol. Retinol (all-trans retinol), as a precursor of retinoic acid, is a major regulator of the 
growth of epidermal cells and of their differentiation. Retinol is metabolized to active metabolites: 
all-trans-retinoic acid (retinyl palmitate, tretinoin) and 11-cis-retinal. Vitamin A  absorbs ultraviolet 
radiation with an absorption maximum of A = 325 nm. Gaspar et al. assessed the photostability 
of vitamin A  in formulations containing chemical UV filters in two combinations differing in their 
photostability: photoinstable, including octyl methoxycinnamate, avobenzone and 4-methylbenzilidene 
camphor; and photostable, including octyl methoxycinnamate, benzophenone-3 and octocrylene [35]. 
The formulations were spread onto glass plates and exposed to UVA/UVB irradiation. The higher 
photostability of vitamin A was observed in both formulations containing UV filters in comparison to 
these not supplemented with UV filters [35].
Tretinoin (all-trans retinoic acid) and izotretinoin (13-cis-retinoic acid) are commonly used topical 
anti-acne agents. They are also used in the treatment of psoriasis and photodamaged skin. These two 
retinoids are very highly sensitive to light. Bassam et al. conducted research on the impact of UV solar 
simulated light, UVA, and visible light on the photostability of tretinoin and isotretinoin in ethanol 
and cream preparations [36] . Both tretinoin and isotretinoin underwent photoisomerization and 
photolysis following irradiation but tretinoin was more susceptible to degradation then isotretinoin. 
However, when comparing their photostability in cream formulations and ethanol, attention was paid 
to their greater stability in ethanol solutions. The authors of the articles explained this in terms of the 
diversity of components present in cream formulations which could interact with the investigated 
drugs by improving their photodegradation. In this context, UVA irradiation (as the major contributor 
to the photodegradation of tretinoin and isotretinoin) deserves special attention [36] . Irradiation 
within a wavelength range of 300-800 nm of ethanol solutions of tretinoin and isotretinoin leads 
to isomerization of tretinoin and isotretinoin to 13-cis and 9-cis isomers, respectively, within a few 
seconds of light exposure. Their incorporation into liposome complexes contributes to improved 
photostability [37]. The photostabilization of tretinoin by liposome incorporation has been the subject 
of numerous studies dealing with the photolability of this API and its formulation problems [38] . 
Brisaert et al. carried out accelerated stability analyses of dermatological preparations containing 
tretinoin including the influence of daylight and temperature only (25, 37, and 45 °C). The research 
revealed that the tretinoin degradation rate was severely affected by the presence of daylight at 
room temperature and at above the mentioned temperatures in all preparations (lotion and four 
hydrogels). 10% degradation of API was reached in the period of time from 1 to 181 h of irradiation 
depending on the formulation of preparation [39]. The studies of the influence of temperature showed 
that tretinoin was the most stable in the lotion, while the highest percentage of degradation was 
reported for Carbopol gel without Brij 35 S. It is clear that solubilizing agents have an impact on 
the stability of API. Therefore, the influence of solubilizing agents on the stability of tretinoin was 
also investigated. A  comparison of the chemical stability of tretinoin in Carbopol gel with Brij 35 S 
and Carbopol gel without Brij 35 S indicates the negative influence of this solubilizing agent on the 
stability of tretinoin [39]. Furthermore, tretinoin in lotion underwent a fast photodegradation process 
in the daylight; on the other hand, the most stable were tretinoin gel preparations: Carbopol gel 
with and without Brij 35 S [39]. Brisaer et al. carried out investigations on tretinoin lotion to assess 
the stabilization effect of additives such as surfactants, cyclodextrins and proteins, dyes, and UVA 
and UVB filters under xenon lamp irradiation. According to the conducted research, tretinoin in 
lotion underwent 20% degradation within 30 min of irradiation and the addition of surfactant (Brij®s) 
or the use of p-cyclodextrin did not improve its photostability [40]. The results of the analysis in 
which tretinoin was irradiated with different radiation lengths were interesting. The most harmful 
wavelength was about 420 nm, which directly contributes to the photodegradation of tretinoin, not 
350 nm—the wavelength of maximum absorption [40]. The combination of tretinoin with antibacterial 
agents, such as erythromycin, benzoyl peroxide, and clindamycin to improve the effectiveness of acne 
therapy is very common [41]. Martin et al. investigated the photostability of tretinoin when combined
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with benzoyl peroxide under visible light and UV radiation. The dark control showed the stability of 
tretinoin, but the presence of light, benzoyl peroxide, and light and benzoyl peroxide alone affected 
its stability under the same conditions. The presence of benzoyl peroxide or benzoyl peroxide and 
light resulted in degradation of about 80% and 95%, respectively, after 24 h [42]. An improvement of 
photostability was achieved after the use of tretinoin in micronized form. Comparison of photostability 
of micronized tretinoin in 0.05% gel with 0.025% gel with standard particle size after exposure to 
ultraviolet radiation and simulated sunlight for 8 h showed the greater photostability of micronized 
tretinoin. The degree of degradation was 11-12%  in both cases of radiation for micronized tretinoin 
and 85-90% for tretinoin in the form of a conventional gel after applying fluorescent light and 84-89% 
after using simulated sunlight [43].
Lai et al. examined the impact of nanoemulsions and nanosuspensions on tretinoin photostability 
The comparison of the photostability of tretinoin in methanol and tretinoin in nanoemulsion and 
nanosuspension was investigated using a 30 W  lamp (366 nm). The samples were irradiated for 
1 h. In the case of the methanolic solution, a residual concentration of 27% was present after 
irradiation. The use of nanoemulsion and nanosuspension improved the photostability of tretinoin. 
The concentrations of 83% and 52% of the initial amount of tretinoin were determined in nanosuspension 
and nanoemulsion, respectively. The half-life time was about 0.4, 0.9, and 3 h for the solution, 
nanoemulsion, and nanosuspension, respectively [44]. An isotretinoin micro-emulsion preparation 
has also been tested for the photostability under simulated sunlight conditions. Isotretinoin methanol 
solutions were a reference in which isotretinoin is completely photodegradable only a few minutes 
after exposure to UV radiation. The measured concentration of the tested substance after 240 min was 
75% of the initial concentration in the micro-emulsion, while in the methanol solution it was completely 
degraded. Isotretinoin micro-emulsion preparation increased the half-life of the medicinal substance 
about 5-fold [45].
Adapalene [6-(3-(1-adamantyl)-4-methoxyphenyl)-2-naphthoic acid] is a naphthoic acid derivative 
with retinoid activity. Adapalene is a result of the search for a molecule more chemically stable than the 
leading topical retinoid tretinoin. This compound has all the benefits of the first-generation retinoids 
with minimization of the retinoid-associated skin irritation [94,95] . In this chemical entity, the chain 
with unstable double bonds is replaced by naphthoic acid. This change has caused an increase in 
stability during light exposure, improved resistance to oxidation by—e.g., benzoyl peroxide— and has 
decreased the irritating properties. Furthermore, the phenoxy adamantyl structure of adapalene has an 
impact on higher lipophilicity and thus on better skin penetration [94]. So far, the following impurities 
of adapalene have been described: impurity A (2,2'-binaphthalene-6,6'-dicarboxylic acid), impurity B 
(6[3(3hydroxytricyclo[3.3.1.1,37]dec1yl) 4methoxyphenyl] naphthalene-2-carboxylic acid), impurity 
C (1-(2-Methoxyphenyl)-tricyclo [3.3.1.13,7]decane), impurity D (1,1'-[4,4'-bis(methoxy)biphenyl-3, 
3'-diyl]bis(tri-cyclo[3.3.1.13,7]decane) [96].
Tolba et al. have developed a sensitive spectrofluorometric method to detect stability for the 
determination of adapalene, which was used during in vitro diffusion tests and in stability studies. 
Forced degradation studies involved alkaline and acidic degradation, oxidative degradation, daylight 
and UV light degradation at 254 and 366 nm for 12 h. Adapalene was stable under alkaline conditions 
(boiling with 2 M NaOH for 2 h), but was susceptible to acidic conditions. The total degradation of 
adapalene was observed after boiling with 1 M HCl for 10 min, whereas boiling with 0.3 M HCl for 
10 min caused degradation of 28% of the parent drug. In terms of oxidative conditions the degradation 
was dependent on the concentration of the H2O2. A key finding of the stress degradation studies was 
the photolysis of adapalene after UVA (366 nm) and UVB (254 nm) irradiation for 12 h. The degradation 
proceeded via: (i) under acidic stress conditions breakage of adamantine group, (ii) during photolysis 
degradation of the naphthalene moiety into the corresponding 2-formyl cinnamaldehyde, and (iii) 
under oxidative conditions— the formation of a 1,4-naphthoquinone derivative [46].
The chemical stability of adapalene in combination with benzoyl peroxide was also investigated 
in the presence and in the absence of UV/VIS irradiation. In this case, a commercial formulation
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of adapalene 0.1% gel was mixed with an equal volume of a commercial formulation of benzoyl 
peroxide 10% lotion and irradiated over 24 h. Adapalene was stable under experimental conditions [42]. 
Roy et al. carried out forced degradation studies of adapalene in the presence of benzoyl peroxide in a 
topical pharmaceutical formulation. After 240 h of exposure to UV/VIS light or after 250 h of exposure 
to UV light, two main photoproducts were observed: benzoic acid (1.6%) and an unknown product 
(0.5%) at the relative retention time of about 0.93. The total percentage of the products was about 
2.24% [47].
Tazarotene (ethyl 6-([4,4-dimethylthiochroman-6-yl]ethynyl)nicotinate) is used in the treatment of 
the most common form of psoriasis; namely, plaque psoriasis. This retinoid added to UVB phototherapy 
contributes to a significant reduction of the cumulative dose of UVB irradiation necessary to achieve at 
least 50% improvement in psoriasis compared to UVB alone or with UVB plus vehicle. [97]. Furthermore, 
the addition of tazarotene significantly enhances the efficacy of narrow-band UVB phototherapy [98]. 
Hecker et al. investigated the photostability of tazarotene gel while conducting in vivo research on the 
simultaneous use of tazarotene and UV light [48]. For this purpose, 2 g of 0.1% tazarotene gel was 
applied on the surface of 40 cm2 of the ventral aspect of the forearms, and then patients were exposed 
to UVB or UVA irradiation for 5 min depending on the recommendations. The research also took into 
account different degrees of psoriasis on the selected areas. After UV irradiation, the gel was collected 
and analyzed by an HPLC method. The concentration of tazaroten and its photoproducts (tazarotenic 
acid and AGN 190832) were determined. The percentages of degradation product AGN 190832 were 
0.90,1.05, and 0.01% for UVB, UVA, and control, respectively. The percentages of tazarotenic acid were 
even lower, 0.00,0.05, and 0.01% for UVB, UVA, and control, respectively [48].
2.3. Antifungal Drugs
Antifungal drugs are characterized by a wide variety of chemical structures and a broad range of 
mechanisms of action. There are many antifungal drugs for both systemic and local use; however, the 
following groups play a special role in modern therapy of fungal infections: azole derivatives applied 
orally and topically, inhibitors of squalene epoxidase, morpholine derivatives, and polyene antifungals.
Azole derivatives have a broad spectrum of activities. The mechanism of action is based on 
fungistatic activity—by inhibiting the biosynthesis of ergosterol which is a component of the fungal 
cell membrane, and fungicidal activity— resulting from the change of the structure of the fungal cell 
membrane that is linked to the accumulation of azole drugs (for example, clotrimazole). However, 
despite their popularity, research into the photostability of azole antifungal drugs is very limited. 
The photodegradation of clotrimazole reaches 40% after 500 min of irradiation by polychromatic 
light according to the method which was developed by ECETOC. The investigated drug content was 
assessed by HPLC-UV, but the structure of photoproducts have not been described. The research was 
carried out in water to assess the fate of clotrimazole in the environment. The OSPAR Commission 
in its Background Document on Clotrimazole states that photolysis does not significantly contribute 
to the removal of this drug from the environment [49]. The assessment of the photostability of 
clotrimazole in methanol solution under UVA irradiation carried out by Kryczyk et al. showed no 
presence of photoproducts after 24 h. This irradiation was carried out in a KBF-ICH 240 APT.line™ 
climatic chamber (Binder GmbH, Tuttlingen, Germany) at 25 °C and 60% relative humidity using 
UVA radiation (320-400 nm) with a maximum emission at 365 nm. The presence of semiconductor 
photocatalysts TiO2 and ZnO under experimental conditions caused photocatalytic degradation of 
clotrimazole through the opening of the imidazole ring or loss of the imidazole moiety. An experiment 
carried out in phosphate buffer in the presence of the same photocatalysts showed the appearance of 
additional photocatalytic degradation products which were created as a result of hydroxylation of the 
phenyl rings [50]. Similar studies were conducted for bifonazole, but a different combination of TiO2  
and/or ZnO was applied. Bifonazole was stable after UVA irradiation in the absence of catalysts and 
in all dark control samples. The photocatalytic degradation of bifonazole was the most efficient in 
the presence of both semiconductors. The determined values of kinetic parameters showed that the
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degradation process depends on the concentration of photocatalysts. Bifonazole photodegradation 
proceeded via hydroxylation of one of the phenyl rings or methanethiol groups, imidazole ring opening 
followed by further cyclization or loss of the imidazole moiety. The identification of photodegradation 
products was based on a UPLC/MS-MS analysis and, as a consequence, 10 photodegradation products 
of bifonazole were identified [51].
Among the triazole derivatives, we can distinguish itraconazole and fluconazole. The mechanism 
of action is based on inhibiting the enzyme responsible for the biosynthesis of ergosterol, which is 
a component of the fungal cell membrane resulting in increased permeability, inhibition of growth 
and fungicidal action. There are some research papers on itraconazole used as a topical dosage 
form [99,100]. Furthermore, it is registered as 1% gel (w/w) in India. Itraconazole has been found 
to be photo-unstable under UVA and UVB irradiation. The irradiation of itraconazole with UVB 
lamps (Hitachi, F15T8/BL, maximum output at ca 300 nm) was performed by Nardi et al. Three major 
photoproducts were formed in acetonitrile solutions, which were separated by preparative HPLC. 
The degradation of itraconazole proceeded via a dehalogenation process in ortho or para position. 
In the case of photoproduct 2 cyclization concerning the triazole moiety was also observed [52]. 
The photochemical properties of this drug are connected with its photosensitivity through generation 
of reactive aryl radicals as a result of the dehalogenation step [52]. Photocatalytic degradation of 
itraconazole in the presence of FeCfi, TiÜ2 , and FeCl3/TiÜ2  is more efficient than its photolysis under 
UVA irradiation. The photodecomposition of itraconazole mainly includes a C-N  bond cleavage 
step and the loss of one of the chloride atoms in the phenyl ring [53]. Kinetic evaluation of the 
photodegradation process has revealed that the activity of catalysts used decreases in the following 
order: FeCl3 > FeCl3/TiO2 > TiO2 [53].
Inhibitors of squalene epoxidase impair the synthesis of ergosterol by blocking the conversion 
of squalene to lanosterol. This group includes two antifungal agents applied topically to the skin: 
terbinafine and naphtyphine. Terbinafine is administered orally; however, due to the significant 
first pass metabolism and plasma protein binding (99%), topical administration of this drug is 
common and preferred [101,102]. Due to its high lipophilicity and keratophilicity terbinafine is 
concentrated in the stratum corneum, dermis, epidermis of the skin, and in the nails [103]. Photostability 
studies of terbinafine in the presence of selected UV filters and cytotoxicity studies of solutions after 
photocatalytic degradation using human skin fibroblast cells (BJ) ATCC™ were carried out by 
Kryczyk et al. [54]. The photodegradation process proceeded via oxidative deamination with the 
formation of 1-methylaminomethylnaphtalene or 1-naphthalenemethanol and loss of the side chain 
(E)-N,6,6-trimethyl-2-hepten-4-yn-1-amine. The formation of Z-terbinafine ((Z)-N,6,6-trimethyl-N- 
(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine) is also possible [54].
The derivatives of morpholine include amorolfine, which is used only topically in the form 
of a cream and nail polish. The mechanism of its action is based on compromising the ability to 
ergosterol synthesis by blocking A14-reductase and then depositing false sterols in the cell membrane. 
No publications describing the stability of this widely used drug have been found.
Polyene antifungal drugs include amphotericin B and nystatin. Nystatin is a polyene antibiotic 
applied topically in the treatment of vaginal yeast infection as well as given orally in oral cavity 
infection. It is practically not absorbed through the skin or mucous membranes, nor is it absorbed from 
the gastrointestinal tract. In the case of amphotericin B, a clinical trial II has been performed to assess 
the safety and efficiency of topical application of amphotericin B cream (Anfoleish) in the treatment 
of cutaneous leishmaniasis [104]. Polyene antibiotics are photodegradable under UV irradiation. 
Amphotericin B and nystatin degrade after 2 h of irradiation. Photochemical instability applies not 
only to APIs but also to drug products [105]. The solubility and photostability of amphotericin B is 
improved by formatting of a complex with cyclodextrin, mainly y-cyclodextrin [106].
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2.4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Non-steroidal anti-inflammatory drugs are among the most commonly used drugs in the 
pharmacotherapy of pain. NSAIDs inhibit prostaglandin synthesis by affecting the activity of 
cyclooxygenase (COX): constitutive COX-1 and induced COX-2 [107]. Baertschi et al. showed 
that 95 out of the 342 topical products authorized in the US which are listed in the USP should be stored 
in a light-protective packaging. In Europe, among topical products marked "protected from light" are, 
inter alia, piroxicam cream, and ibuprofen gel. Most of the NSAIDs are photoreactive; therefore, their 
photochemical properties have been investigated in detail. In addition, application of drugs from this 
group to the skin could be the source of drug-induced photosensitivity. Phototoxic and photoallergic 
reactions may appear as a result of both systemic or topical administration of NSAIDs, but higher 
concentrations in the skin after topical application of drugs lead to a higher frequency of photosensitivity 
for this route of administration [108].
Piroxicam is one of the NSAIDs which causes skin sensitivity to sun and therefore the photochemistry 
of this drug is a widely studied topic. Piroxicam belongs to the oxicam group of NSAIDs. It has a 
strong anti-inflammatory, as well as analgesic and antipyretic effect. The action of piroxicam is mainly 
based on the inhibition of cyclooxygenase (both COX-1 and COX-2). These enzymes participate in 
reactions that lead to the formation of prostaglandins from the lipids of cell membranes. Piroxicam is an 
oxicam derivative (4-hydroxy-2-methyl-N-(2-pyridyl) -2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide), 
which differs structurally from other NSAIDs. The photodegradation of an ammonia solution (pH 11.8) 
containing three different concentrations of this compound (40 pg mL-1, 250 pg mL-1 and 2 mg mL-1) 
was concentration-dependent under irradiation by simulated sunlight for 480 min. Almost 100% of 
the initial amount of piroxicam was degraded after 288 min at a concentration of 40 pg mL-1 and 
after 480 min at a concentration of 250 pg mL-1 . In the case of the highest concentration, 75.96% 
of the initial concentration underwent degradation [55]. Aminuddin et al. assessed the percentage 
of piroxicam photodegradation in buffer solution depending on the pH. The relationship between 
pH and the degradation rate is U-shaped, with an increase in the degradation rate in acidic and 
alkaline regions [109]. The inclusion complex of piroxicam with 2-hydroxypropyl-p-cyclodextrin 
increases the photostability by offering protection from daylight for up to 30 days [56]. Glass et al. 
identified four photodegradation products of piroxicam after irradiation of its methanolic solution: (i) 
2-methyl-1,2-benzisothiazol-3(2H)-one1,1-dioxide; (ii) N-(2-pyridyl)-methoxy-formyl-amide as a result of 
oxygen incorporation into piroxicam; (iii) N -(2-pyridyl)-methoxyamide being a result of decarbonylation 
of N-(2-pyridyl)-methoxy-formyl-amide; and (iv) N-methyl-N'-(2-pyridyl)-ethane-diamide formed as a 
consequence of cleavage of the sulfur-nitrogen bond in the carboxylic acid. There was no statistically 
significant effect of 2-hydroxypropyl -p-cyclodextrin on the rate of piroxicam photodegradation [57].
The photostability of two well-known anti-inflammatory APIs was tested by Sammartino et al. 
After being dissolved in ultrapure water, diclofenac, and naproxen were irradiated using a light source 
that simulated sunlight (a mercury-vapor lamp coupled to a tungsten filament one) at 25 ± 1 °C. 
After the irradiation of the investigated samples for 90 h, an 88.4% and 91% decrease in the tested 
API concentrations for naproxen and diclofenac, respectively, was observed. The irradiance used 
during the experiment equaled 600 W/m2 which corresponds to the minimal irradiation during the 
sunniest hours during the day in Italy. Under the experimental conditions, the photodegradation 
rate was higher for diclofenac compared to naproxen in both dosage forms: solution and tablets [58]. 
The photodegradation process of diclofenac in aqueous solution was found to proceed via loss of 
one chlorine, then ring closure and chlorocarbazole acetic acid formation followed by the loss of the 
second chlorine and formation of hydroxycarbazole and its reduced product [57,62]. Drugs which 
cause photosensitivity commonly contain a chloroaromatic moiety. Diclofenac has been reported to be 
a photosensitive drug and the mechanism is based on free radical photodechlorination [57].
Solutions of diclofenac were also irradiated with a medium pressure 400 W mercury lamp in the 
presence and in the absence of cyclodextrins. The study of the impact of 2-hydroxypropyl-p-cyclodextrin 
on the photostability of diclofenac indicated that initially diclofenac in solution appeared to be
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more stable compared to the complex and after 30 min of irradiation the complex had higher 
photostability [57].
Naproxen was also found to undergo photolysis. The structures of naproxen photoproducts 
were determined using LC-ESI/MS by Hsu et al. [59]. Four degradation products were described 
in methanol solution after irradiation with a low-pressure quartz mercury lamp for 3 days:
1-(6-methoxy-naphthalen-2-yl)-ethanol, 1-(6-methoxy-naphthalen-2-yl)ethanone, methyl 2-(6-methoxy- 
naphthalen-2-yl)propanoate, and 2-ethyl-6-methoxynaphthalene [59]. Arany et al. additionally 
investigated the impact of UV (254 nm), VUV (172 nm), and UV/VUV (254/185 nm) on naproxen 
photolysis. Under experimental conditions, the photodecomposition depended on the applied 
irradiation decreasing in the following pattern: UV > VUV > UV/VUV [60]. The ecotoxicity of 
naproxen and its photodegradation products was assessed by Isidori et al. [61]. An assay performed 
on the rotifer B. calyciflorus, crustaceans: C. dubia and T. platyurus, and the alga P. subcapitata showed 
that photoproducts were more toxic than naproxen. Genotoxicity tests did not show genotoxic and 
mutagenic effects of degradation products [61].
Topical application of naproxen or ketoprofen can result in the phototoxic and photoallergic 
reaction after UVA irradiation. Ketoprofen is the most common cause of the photosensitivity induced by 
NSAIDs. UV photolysis of ketoprofen was carried out with a low pressure (LP) Hg lamp (A = 254 nm) 
and the applied exposure time corresponded to 0, 100, 500, 750, 1000, and 1500 m J cm -2 [110]. 
Photolysis with a UV Hg lamp, medium pressure (MP), was carried out using a mixture of compounds: 
ketoprofen, diclofenac, and atenolol in pure water. The experiment allowed the proposing of 
phototransformation pathways for photolysis and identification of the degradation products of 
the investigated compounds. The major products of ketoprofen in LP and MP photolysis are
2-(3-(carboxyoxomethyl)phenyl)propanoic acid and 2-(3-(carboxy(hydroxy)-methyl)phenyl) propanoic 
acid arising as a result of oxidative ring opening [110]. The UV (254 nm) photolysis of ketoprofen 
and ibuprofen was also investigated by Szabo et al. [63]. After 90 s of irradiation, ketoprofen was 
completely degraded. Four photoproducts were identified i.a. 3-hydroxyethyl benzophenone which 
had been described earlier by Matamoros et al. [63,64]. Under UV irradiation, ketoprofen underwent 
degradation, which in vitro in the presence of rat hepatocytes, fibroblasts, or red blood cells was 
connected with the formation of radical intermediates and damage to the cell membrane, as well as 
membrane lipids peroxidation and red blood cell hemolysis [65,66]. Furthermore, ketoprofen may 
cause the induction of DNA damage and formation of pyrimidine dimers [108]. Atarashi et al. revealed 
that the addition of butyl methoxydibenzoylmethane into a topical formulation containing ketoprofen 
reduced the photoallergic reaction caused by this drug. Butyl methoxydibenzoylmethane is a UVA filter, 
but unlike octocrylene and benzophenone-3 shows no cross-reactivity with ketoprofen [111]. It should 
be emphasized that the benzophenone moiety in ketoprofen plays a key role in its photosensitivity 
reactions. Hence, patients with a photoallergic reaction to ketoprofen should avoid sunscreen containing 
octocrylene and benzophenone-3.
Ibuprofen is a traditional NSAID commonly used for its analgesic and anti-inflammatory properties. 
Ibuprofen is a non-selective, reversible inhibitor of COX-1 and COX-2. It is considered to be relatively 
stable but, in aqueous solution, it undergoes direct photolysis and self-sensitization which is based on 
photo-oxidation. The major photoproducts of ibuprofen have been identified as 1-(4-isobutylphenyl) 
ethanol and 4-isobutylacetophenone [67]. Furthermore, the generated photoproducts of ibuprofen 
are more toxic than the parent drug [67,68]. 4-isobutylacetophenone, which can be formed in the 
environment during direct photolysis and reactions with OH* and with the triplet states of chromophoric 
dissolved organic matter was toxic to cell membranes, causes protein dysfunctions and protein stress, 
and affects the nervous system [69- 71].
2.5. UV Filters
Efficient sun protection could be provided by synergistic action of various combinations of 
inorganic and organic UV-filters. Physical filters such as TiO2 and ZnO reflect and scatter UV radiation.
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These are filters showing a wide spectrum of protection against both UVA and UVB. ZnO is more 
effective in the UVA range, while TiO2  better protects against UVB and short-wave UVA, which is 
why they are often used together. They are stable, but leave a white layer on the skin, which is why 
they are currently used in micronized form. Chemical filters are organic compounds that have a high 
molar absorption coefficient in the UV range (100-400 nm). Chemical solar filters work by absorbing 
radiation due to the presence of numerous unsaturated bonds and moieties with free electron pairs. 
Absorption can lead to photochemical reactions in these molecules, such as trans-cis transformation, 
or keto-enol tautomerism. Chemical filters can be divided into several groups: p-aminobenzoic 
acid derivatives— 4-aminobenzoic acid (PABA), benzophenone derivatives—benzofenone-3 and 
sulisobenzone, salicylic acid derivatives— homomenthyl salicylate (homosalate), cinnamic acid 
derivatives— octyl methoxycinnamate (OMC), camphor derivatives— 4-methylbenzylidene camphor 
(4-MBC), triazine derivatives— bis-ethylhexyloxyphenol methoxyphenyl triazine (Tinosorb S), 
methylene bis-benzotriazolyl tetramethylbutylphenol (Tinosorb M), and others. Another division was 
made due to protection in the specified UV range— PABA and OMC, homosalate, 4-MBC protecting 
in the UVB range; butyl methoxydibenzoylmethane (avobenzone), benzofenone-3, Mexoryl SX and 
Mexoryl XL protecting in the UVA range; and Tinosorb S, Tinosorb M, and octocrylene protecting 
in the UVA and UVB range. Parsol SLX is an oligomer belonging to the new generation of filters 
protecting against UVB radiation with a maximum absorption of 310 nm (Polysilicone-15).
The photoinstability of filters could result in a change to their photoprotective proprieties and 
safety profiles. Organic UV filters after absorption of UV radiation may lose their excitation energy 
through, e.g., chemical transformation. In the case of reversible transformations, the system is stable, 
unlike non-reversible transformation where photodegradation occurs. The capability to dissipate 
excitation energy via reversible transformations, e.g., E/Z isomerization, is a desirable process for 
UV filters, but requires evaluation of absorption curves in terms of their shape and the magnitude 
of extinction coefficients for mixtures of E/Z isomers. The E ^  Z fast and reversible isomerization 
of benzylidene camphor derivatives, e.g., 4-MBC, when irradiated by UV is commonly known [72]. 
Absorption of UVA irradiation could lead to trans-cis isomerization, which is in accordance with 
the assumption that the most probable photochemical reaction for derivatives of cinnamic acid is 
trans-cis photoisomerization [73]. Broadbent et al. likewise defined one degradation product as a result 
of photostability studies (UV irradiation at wavelengths 313 nm) of ethylhexyl methoxycinnamate 
(trans-EHMC). Cis-2-ethylhexyl-p-methoxycinnamate is a product that results from the conversion of 
trans-EHMC. Furthermore, trans-EHMC  irradiated at wavelengths above 300 nm with more intense 
source has undergone photodimerization via a cycloaddition reaction [74]. Therefore, one of the 
most important characteristics of organic UV filters is photostability. Chemical filters can absorb 
the radiation, which can cause chromophore destruction and thus lead to a decrease or even loss 
of its ability to absorb energy through photoisomerization processes (avobenzone, OMC) [75,78,79] 
fragmentation, and generation of free radicals [112] or photoaddition [76]. These are not reactions 
based on the 'all or nothing' response, but there is a gradual loss of filter protective properties over 
time, and the resulting photoproducts and free radicals with unknown properties can react with other 
cream ingredients, skin, and sebum, which may cause phototoxic, photoallergic, and other toxicological 
effects that are difficult to predict. High photostability of the mentioned chemical UV filters is an 
important and desirable requirement to achieve the effectiveness of sunscreen products. In recent 
years, the use of avobenzone and other UVA filters has increased significantly due to the proven 
harmfulness of this radiation. Research is being conducted into the stability of already use filters not 
only in the context of determining the structure of degradation products, and kinetic parameters of the 
degradation process but also in the context of safety of use in both in vitro and in vivo tests [35,113,114]. 
There are increasing numbers of reports about the impact of UV radiation on the photodegradation of 
specific chemical filters and their combinations providing full protection in both UVB and UVA. It turns 
out that some combinations are very unfavorable for the photostability of UV absorbers, while others 
improve the initial stability of UV filters [115]. The best known example is avobenzone, which is the
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most commonly used chemical filter due to its strong protection in the range from 310 to 400 nm with a 
maximum at 360 nm [77]. However, it has been pointed out that avobenzone requires the presence of 
UVB filters— e.g., octocrylene or 4-MBC— then these substances prevent its degradation, which leads 
to strengthening of its protective capabilities and stability. That is why modern preparations contain 
both UVB and UVA filters to ensure a full spectrum of protection.
Avobenzone is 50-90%  photodegradable after one hour of exposure to UV radiation, and should 
not be combined with any of the most commonly used UVB trans-EHMC and OMC filters because as a 
result of the reaction between them a new compound is formed, which leads to loss of UVA and UVB 
protection [76,77]. The commonly used OMC also undergoes degradation. Tinosorb S prevents the 
photodegradation of avobenzone, but also acts photoprotectively in creams simultaneously containing 
avobenzone and OMC [76].
In recent years, the problem of the photostability of drugs during administration appears to 
be increasingly emphasized and discussed [17,21]. This is in particular an issue for drugs used in 
topical preparations because their application on external body surfaces causes a high probability of 
exposure to UVR. Additionally, there is a high probability of interaction of topical pharmaceutical 
products used concomitantly with cosmetics. It should be pointed out that cosmetics might contain 
different ingredients such as inorganic UV filters (nanoparticles of ZnO or TiO2 ) which may show a 
high photocatalytic activity. Organic UV absorbers could be used in the photostabilization process 
of photolabile drugs. This strategy has been used in the case of diclofenac and ketoprofen, where 
stabilization was achieved by use of EHMC or ethylhexyl salicylate [116]. In contrast, light energy 
equal to or higher than a bandgap of TiO2  or ZnO (A < 380 nm) generated an electron in a conductive 
band (eCB- ) and a positive hole in the valence band (hvB+) pair. The holes in the valence band, as strong 
oxidizing agents, could generate hydroxyl radicals (OH*). Furthermore, the electrons in conduction 
band reduce oxygen to O* radicals. Additional reaction can lead to the formation of hydrogen peroxide 
and OH*. The reactive oxidizing species could lead to oxidation of the organic compounds [117- 120].
TiO2 +  hv (< 380 nm) ^  eCB +  h+B (1)
ZnO +  hv (< 380 nm) ^  eCB +  h+B (2)
H 2 O +  h+B ^  *OH +  H+ (3)
eCB +  O2 ^  O* (4)
O 2  +  2H+ +  eCB ^  H 2 O 2 (5)
H 2 O2  +  eCB ^  *OH +  OH- (6)
OH-  +  h+ ^  *OHvB (7)
H+ +  O*-  ^  * HO2 (8)
3. Photostabilization Strategies of Selected Dermatological Drugs
Dermatological preparations are mainly semisolid dosage forms applied to the skin. Different 
methods are required to test their photostability than for solid or liquid preparations. Different methods 
of photostabilization are also recommended. Furthermore, it is necessary to verify the stability of the 
API in the tested dosage form, as a substance stable in solution may turn out to be unstable in, e.g., 
cream. In this context, research dealing with the photodegradation of dermatological drugs as well as 
photostabilization strategies is summarized in Table 3 . The main factors playing an important role 
in overcoming photoinstability are: formulation factors, UV-absorbers and pigments, antioxidants, 
cyclodextrins inclusion, vesicular systems, and combination of different techniques [20,21,38,84].
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A ctive Pharm aceutical 
Ingredients
Photostabilizers/Excipien ts Form Percent Loss Irrad iation D ose/T im e/Type/Source Ref
control 49 .2  ±  0.92
titanium  d ioxide (light scattering) 17.78 ±  1.24
U V  lam p (300 W, U ltra-V ita lux O sram ) 
3 0 0 -4 0 0  nm ,
[2 7 ]B etam eth ason e valerate v a n illin  (radical scavenger) cream 27.6 ±  1.36 the in ten sity  of ligh t-16  000 lx,
b utyl h yd roxyto luen e (radical 
scavenger)
31.0 ±  1.22
up to 2 h  of irrad iation
control 42 .5  ±  1.64
titanium  d ioxide (light scattering) 7.2 ±  0.98 U V  lam p
[2 7 ]B etam eth ason e valerate v a n illin  (radical scavenger)
gel
13.8 ±  1.44
(3 0 0 -4 0 0  nm) 
the in ten sity  of ligh t-16  000 lx
b utyl h yd roxyto luen e (radical 
scavenger)
21.9 ±  1.60
B etam eth ason e valerate  cream
control (w ith ou t the preservative) about 30% U V B
[2 5 ]chlorocresol
(excip ient-preservative)
top ical o in tm en t 0.1%
less th an  10%
(5 J/cm2) -
Ph ilip s PL -S  9W/12 lam p m ain ly  em ittin g  at 312 nm
control (w ith ou t the preservatives) 40%
U V B
H yd rocortison e 21-acetate parabens: m eth yl- and propyl 
p -h yd roxy ben zoates 
(excip ients— preservatives)




P h ilip s PL -S  9W/12 lam p m ain ly  em ittin g  at 312 nm
[2 9 ]
Triam cinolone acetonid e
control (w ith ou t the preservatives) 38% 3 h  of irrad iation ,
[8 4 ]
p igm en ted  cream s (ZnO , TiO2) 95% Sun test C P S + , 415 W/m2
D eson id e
control 61% U VA  irrad iation  (1350 W  h/m2) [3 4 ]
b en zop h en o n e-3  (UV-filter, 0.3%) 1.49% 15 h of irrad iation
control: 0 .6%  (w/w) v itam in  A  
p alm itate  (1 ,700,000 Utyg)
n.d.
30 m in UVA/UVB irrad iation  (2 8 0 -4 0 0  nm)
V itam in  A
octyl m eth oxycin n am ate, 
avobenzone, 4-m eth y lben zilid en e 
cam p hor
top ical form u latio n
enhanced  v itam in  A  stability




octyl m eth oxycin n am ate, 
b en zop h en o n e-3 , octocrylen e
enhanced  v itam in  A  stability
Tretinoin
solu tion ethanolic solu tion 92% Sun set C PS+  (H eraeus)-xen on  lam p (3 0 0 -8 0 0  nm )
[3 7 ]
liposom es liposom es 40% 250 W/m2 for 240 m in
Tretinoin
m icronized  tretin oin  (0.05% ) g el 9% U VA  ligh t (3 1 5 -4 0 0  nm ) [4 3 ]
tretin oin  (0.025% ) gel 72% 22 W/m2
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A ctive Ph arm aceu tical 
Ingredients
Photostabilizers/Excipien ts Form Percent Loss Irrad iation D ose/T im e/Type/Source Ref
Tretinoin
control: M eth an olic  solu tion 63%
1 h  o f irradiation ,
[4 4 ]
N an osu sp en sion  tretin oin  (0.035% ) n an osusp en sion 17% 30 W  lam p -366 nm  (M in U V IS, D esag a, G m bH , G erm any)
N an oem u lsion  tretinoin  (0.035% ) n an oem ulsion 48%
Tretionoin
control: m ethanolic solu tion in corp o ration  in  v esicles  a lw ay s im p roved  the 
p h otostability  of tretinoin
U V  lam p set at 366 nm  (M in U V IS , D esaga, G m bH ) 
fluorescen t light
[121]
n iosom es tretinoin v esicu lar suspensions
Isotretinoin
control m ethanol solu tion 84%
natural sun ligh t (>20,000 Lux) [4 5 ]
m icro-em ulsion  
tretin oin  (0.035% )
m icro-em ulsion
form u latio n
25%
D iclofenac
control solu tion the drug ap p ears to b e  m ore stable  th an  the 
com p lex for T  < 30 m in  and thereafter degrades 
rap id ly  (the com p lex  is m ore stable)
400 W  m ercury  lam p [5 7 ]
2-h ydro xyp rop yl-




n ot affected  the rate  o f photod egrad ation n.d. [5 7 ]
2 -h y d ro xy p ro p y l-3 -cy clo d extrin p iroxicam -p -cy clod extrin
control piroxicam
Piroxicam 2 -h y d ro xy p ro p y l-3 -cy clo d extrin
piroxicam :2-hydroxypropyl- 
p -cyclod extrin  com p lex
com p lex im p roved  photostability d aylig h t up to 30 days [5 6 ]
A vobenzone
control p repared form u latio n
5 6 % -7 0 %  (d ifferent con cen tration  of 
avobenzone)
op tically  filtered xen o n  arc source 
(M ultiport Solar U V  sim ulator, Solar light, Philadelp hia, PA, 
U SA )
U V  irradiance ad justed  at 1 m ean effective dose [MED]/min
[7 6 ]
tin osorb  S
form u latio n  w ith  
tin osorb  S
5 % -15%
n.d.—not defined.
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4. Drug-Induced Photosensitivity
Initially, increased interest in sunscreens was related to the existing relationship between exposure 
to UV radiation and skin aging and pigmentation disorders; that is, aesthetic considerations. It is now 
well known that protection against UV radiation is extremely important for health reasons. Adverse 
effects of UV radiation include burns, photodermatoses (polymorphous light eruption, urticaria), 
and photoallergic and phototoxic reactions. Furthermore, light sensitive substances applied to the 
skin, e.g., perfumes, essential oils, drugs, or molecules supplied to the skin by the circulatory system 
(e.g., hypericin or selected cardiovascular drugs and antibiotics), might induce photosensitivity. 
Drug-induced photosensitivity is associated with the presence of two agents: light (ultraviolet or visible 
radiation) and drug (systemically or locally administrated). Photosensitivity reactions are classified as 
phototoxic reactions or photoallergic reactions, which are often difficult to distinguish. UVA radiation 
(320-400 nm) is much more often responsible for inducing hypersensitivity reactions to light because of 
deeper penetration into the skin. Many drugs—e.g., retinoids, salicylates, cinnamates, benzophenones, 
itraconazole, and voriconazole— are responsible for the photosensitivity reactions. Table 4 contains 
selected drug classes that have been reported to induce photosensitivity reactions. Phototoxicity is 
an acute reaction caused by damage initiated by the light-induced degradation of photoreactive or 
photoactive molecules. Because of the presence of chromophores in a drug's structure, their molecules 
absorb high-energy UV radiation which results in molecular changes or generates reactive oxygen 
species [122,123]. The active pharmaceutical substance or its metabolite must be present in the skin 
tissue during UV irradiation. Depending on the type of reaction with endogenous molecules following 
the energy absorption by drug molecules, mechanisms of phototoxicity are categorized into two modes 
of action: direct, when a drug directly reacts with the endogenous molecules; and indirect, when 
photoproducts react with endogenous molecules [124]. Symptoms include skin irritation, erythema, 
pruritus, and edema, which are similar to those with excessive sunburn only in regions exposed to the 
sun. Photoallergic reactions are rare, independent of dose, and appear after a few days of exposure to 
radiation. They are associated with the immune cell response, the drug or its degradation products 
act as haptens, via antigen presenting cells or T lymphocytes, which triggers an allergic reaction on 
repeated exposure [122- 125]. Currently, the most appropriate test for the phototoxicity testing of 
soluble compounds is OECD TG 432 (in vitro 3T3 NRU phototoxicity test) [126]. Phototoxicity is 
assessed on the basis of the average cell viability (base cell-BALB/c 3T3 cell— mouse fibroblast) in the 
presence of the tested compound under UV/VIS irradiation or without it [124].
Table 4. Photosensitizing drugs used in dermatology.


















































































Photodegradation of APIs may occur during a drug's production process; its packaging, 
warehousing, or storage; as well as its correct use by patients. The photodegradation process 
of drugs poses a risk due to possible loss of API and formation of by-products with unknown effect. 
The assessment of a drug's photostability requires a comprehensive approach. There are many factors 
to be considered such as the concentration of API, intensity and wavelength of irradiation, pH, polarity 
of solvents, and excipients. The overall objective of the review was to collate knowledge on the 
photostability of drugs applied to the skin, as well as factors potentially affecting this process.
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